3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
11
Prostatic Neoplasms
7
Neoplasm Metastasis
5
Ovarian Neoplasms
4
Neoplasms
4
Triple Negative Breast Neoplasms
3
Endometrial Neoplasms
3
Small Cell Lung Carcinoma
2
Fallopian Tube Neoplasms
2
mCRPC
1
Wilms Tumor
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Pheochromocytoma
1
Pathologic Complete Response
1
Paraganglioma
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Interventions
enzalutamide
2
tislelizumab
1
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
mCRPC
×
talazoparib
×
1 year
×
Clear all
NCT03395197
2026-04-22
TALAPRO-2
Pfizer
Phase 3
Active not recruiting
1,054 enrolled
21 charts
1 FDA